Algert Global LLC Makes New $2.79 Million Investment in Maze Therapeutics, Inc. $MAZE

Algert Global LLC purchased a new stake in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 93,357 shares of the company's stock, valued at approximately $2,786,000. Algert Global LLC owned approximately 0.17% of Maze Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently made changes to their positions in the company. Royal Bank of Canada lifted its holdings in shares of Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company's stock valued at $27,000 after purchasing an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. grew its holdings in shares of Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock worth $42,000 after buying an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Maze Therapeutics during the fourth quarter worth about $43,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Maze Therapeutics in the 2nd quarter valued at approximately $48,000. Finally, Russell Investments Group Ltd. lifted its stake in Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company's stock valued at $49,000 after acquiring an additional 1,725 shares in the last quarter.

Insider Activity at Maze Therapeutics

In other Maze Therapeutics news, CEO Jason V. Coloma sold 34,501 shares of the company's stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total value of $1,034,339.98. Following the sale, the chief executive officer owned 23,337 shares in the company, valued at $699,643.26. This represents a 59.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of the firm's stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $27.61, for a total value of $445,680.62. Following the completion of the sale, the chief marketing officer directly owned 16,142 shares of the company's stock, valued at approximately $445,680.62. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 108,110 shares of company stock worth $3,057,531. Insiders own 5.30% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on MAZE shares. Wall Street Zen cut shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. TD Cowen raised shares of Maze Therapeutics to a "strong-buy" rating in a research report on Monday, August 24th. Finally, BTIG Research reiterated a "buy" rating and issued a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $66.00.

Maze Therapeutics Stock Performance

NASDAQ MAZE opened at $27.44 on Friday. The firm has a market capitalization of $1.52 billion, a P/E ratio of -10.89 and a beta of 2.21. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The firm's fifty day moving average price is $28.74 and its two-hundred day moving average price is $31.90. Maze Therapeutics, Inc. has a 1 year low of $13.89 and a 1 year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting analysts' consensus estimates of ($0.76). As a group, research analysts anticipate that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

About Maze Therapeutics

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

Want to see what other hedge funds are holding MAZE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source